Cipla gets EIR from USFDA for Kurkumbh facility

Pharma major Cipla on Monday said it has received the establishment inspection report (EIR) from the US health regulator after inspection of the Kurkumbh facility in Maharashtra. The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said. The company has received the EIR indicating closure of inspection, it added. Shares of Cipla gained 0.75 per cent at ₹553.70 on the BSE.